retatrutide phase 2 weight loss results of a new medication, Retatrutide, showed the highest amount of in a clinical trial so far. 24% of body weight lost. An average of 58 pounds over 48 weeks! The medical management of Triple hormone receptor agonist retatrutide

As well as telling the pancreas to make more insulin, which helps convert food into energy, the GLP-1 hormone feeds back to the brain and makes users feel full

In another study , patients without T2D were more likely to stop using GLP-1 drugs: about 65% discontinued within a year, compared to 46% of those with type 2 diabetes

Whey protein was studied in a group of obese women pursuing weight loss

Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist with no MHRA marketing authorisation in the UK as of 2025

The findings indicate that: 67% of Omada members were persistent on their medication at one year and experienced weight loss comparable to clinical trials Average weight loss at one year in the program was 18.4% for members persistent on medication and 13.1% for members who discontinued before one year In terms of engagement, members completed more than 10 actions a week on average This data suggests that providing the right kind of support to promote GLP-1 persistence can help patients achieve clinical trial-level weight loss, setting the stage for cardiometabolic disease risk reduction

Are there alternatives for patients who cant tolerate metformin